Exciting advances are occurring in the understanding of the molecular pathogenesis of squamous head and neck cancers. Epidemiology, staging and screening, as well as premalignancy, chemoprevention and the molecular biology of head and neck cancer, lay the groundwork for the understanding of the clinical chapters that follow. Controversial treatments will be compared to the standard management of patient care. Therapy chapters are divided into stage or category specific (resectable advanced, unresectable advanced or metastatic) problems, allowing the reader to review the current standards and options for patient types or specific patients easily. Considerations of supportive care, late toxicities and quality of life, often overlooked are reviewed in detail. This is a comprehensive summary of the current state of the art research and treatment.

Imaging is crucial in the multidisciplinary approach to head and neck cancer management. The rapid technological development of recent years makes it necessary for all members of the multidisciplinary team to understand the potential applications, limitations, and advantages of existing and evolving imaging technologies. It is equally important that the radiologist has sufficient clinical background knowledge to understand the clinical significance of imaging findings. This book provides an overview of the findings obtained using different imaging techniques during the evaluation of head and neck neoplasms, both before and after therapy. All anatomic areas in the head and neck are covered, and the impact of imaging on patient management is discussed in detail. The authors are recognized experts in the field, and numerous high-quality images are included. This second edition provides information on the latest imaging developments in this area, including the application of PET-CT and diffusion-weighted magnetic resonance imaging.

The purpose of this book is to provide a current perspective on the epidemiology head and neck cancer. Cancers of the oral cavity, pharynx, and larynx comprise an important group of tumors with diverse international patterns of incidence and mortality, established risk factors, suggested association with a virus, and potential genetic susceptibility determinants. These tumors offer a unique insight into mechanisms of cancer initiation and progression and gene-exposure interaction.

A working group of sixteen experts from seven countries re-evaluated the evidence of the carcinogenicity of betel-quid and areca-nut chewing and some areca-nut related nitrosamines. Betel-quid and areca-nut chewing are widely practised in many parts of Asia and in Asian-migrant communities elsewhere in the world. There are hundreds of millions of users worldwide. They evaluated betel quid with tobacco as carcinogenic to humans (Group 1) on the basis of sufficient evidence of an increased risk of cancer of the oral cavity, pharynx and oesophagus. The working group reviewed epidemiological studies of human cancer, mainly studies from India, Pakistan and Taiwan (China). Studies on betel quid with tobacco and areca nut with tobacco in experimental animals now also provide sufficient evidence of carcinogenicity. The working group also evaluated betel quid without tobacco as carcinogenic to humans (Group 1), on the basis of sufficient evidence of an increased risk of oral cancer. Studies on betel quid without tobacco and areca nut without tobacco in experimental animals now also provide sufficient evidence of carcinogenicity. Areca nut, a common ingredient of betel quid and many different chewing preparations, including those available commercially, has been observed to cause oral submucous fibrosis

Tumor biology varies at different subsites in the oral cavity, and therefore carcinoma of the gingivo-buccal sulcus (also known as Indian cancer) behaves differently from carcinoma of the tongue. Oral cancer is very often diagnosed at an advanced stage with neck metastasis, and most cases have a guarded prognosis. Loco-regional recurrences are frequent and morbidity following treatment is considerable. However, results have improved in recent years, particularly in early and certain advanced stages, due to better imaging and case selection, improved surgical techniques, including those for reconstructive surgery, a multidisciplinary team approach and a better understanding of tumor biology and prognostic factors. This book comprehensively and systematically reviews all these aspects of diagnostic and therapeutic advances in oral cancer, particularly discussing early detection, epidemiology, chemoprevention and current research. Written by specialists who are active leaders in basic sciences or clinical fields, the chapters address individual and collective issues in managing patients with oral cancer, and provide insights into various treatment approaches. The authors share their knowledge and experience and provide extensive literature sources to encourage clinicians to be flexible, innovative and help them make the best, educated decisions for individual patients.

​This second edition ​provides a comprehensive view of consolidated and innovative concepts, in terms of both diagnosis and treatment. Written by leading international physicians and investigators, this book emphasizes the necessity of combining local and systemic treatments to achieve the objective of yielding higher cure rates and lower toxicities. Heavily updated from the previous edition, it highlights new surgery and radiotherapy techniques, disease awareness, patient quality of life, and comprehensive management. Head-and-neck cancers are a complex clinical entity and their response to treatment is also known to vary markedly in function of host-related factors. Notwithstanding the impressive progresses observed in the field of imaging, head and neck cancers are often diagnosed at a late stage and the presence of locally advanced disease in a significant number of patients implies the use of aggressive treatments in order to both ensure local disease control and reduce distant metastasis risks. In comparison with the first edition, Head and Neck Cancer, Second Edition provides a detailed update of innovative concepts in chemo- and bio-radiation, viral infection impact on tumor growth and response to treatment, and impact of tumor- and host-related factors on treatment outcome.

The WHO Classification of Head and Neck Tumours is the ninth volume in the 4th Edition of the WHO series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies evaluating response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. The book, prepared by 135 authors from 35 countries, contains more than 600 color images and tables, and more than 2700 references. This book is in the series commonly referred to as the "Blue Book" series.